Patents by Inventor Christopher J. Bond

Christopher J. Bond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230060292
    Abstract: Provided herein are cells, such as iNKT cells that include a split dual targeting chimeric antigen receptors (CARs), and methods of use. The split CARs are each linked to an invariant TCR alpha or TRC beta chain.
    Type: Application
    Filed: July 25, 2022
    Publication date: March 2, 2023
    Inventor: Christopher J. Bond
  • Patent number: 10960088
    Abstract: Provided are macrocyclic compounds and iron or cobalt coordinated macrocyclic compounds. The compounds can be used as MRI contrast agents. Certain compounds are redox active and can be used to assess the biological redox status of a sample.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 30, 2021
    Assignees: The Research Foundation for The State University of New York, Health Research, Inc.
    Inventors: Janet R. Morrow, Pavel B. Tsitovich, Sarina J. Dorazio, Abiola O. Olatunde, Joseph A. Spernyak, Patrick Burns, Eric M. Snyder, Christopher J. Bond
  • Patent number: 9873726
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 23, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Publication number: 20170267776
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: February 22, 2017
    Publication date: September 21, 2017
    Inventors: Austin L. GURNEY, Christopher J. Bond
  • Patent number: 9598497
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 21, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Christopher J. Bond
  • Publication number: 20170002054
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 5, 2017
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
  • Patent number: 9422546
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 23, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Publication number: 20160228581
    Abstract: Provided are macrocyclic compounds and iron or cobalt coordinated macrocyclic compounds. The compounds can be used as MRI contrast agents. Certain compounds are redox active and can be used to assess the biological redox status of a sample.
    Type: Application
    Filed: September 12, 2014
    Publication date: August 11, 2016
    Inventors: Janet R. MORROW, Pavel B. TSITOVICH, Sarina J. DORAZIO, Abiola O. OLATUNDE, Joseph A. SPERNYAK, Patrick BURNS, Eric M. SNYDER, Christopher J. BOND
  • Publication number: 20160108130
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 30, 2015
    Publication date: April 21, 2016
    Inventors: Austin L. GURNEY, Christopher J. BOND
  • Patent number: 9181333
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: November 10, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Christopher J. Bond
  • Publication number: 20150315565
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: April 3, 2015
    Publication date: November 5, 2015
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Alexandra L. L. Lazetic, Christopher J. Bond
  • Patent number: 9023621
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: May 5, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Patent number: 8945878
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Publication number: 20140017253
    Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 16, 2014
    Applicant: ONCOMED PHARMACEUTICALS, INC
    Inventors: AUSTIN L. GURNEY, CHRISTOPHER J. BOND
  • Publication number: 20140005077
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
  • Publication number: 20140005076
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
  • Patent number: 8551715
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: October 8, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Publication number: 20110287979
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: February 11, 2011
    Publication date: November 24, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Patent number: 7785903
    Abstract: The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: Christopher J. Bond, Sachdev Sidhu